Literature DB >> 8837158

Medication noncompliance and substance abuse among patients with schizophrenia.

R R Owen1, E P Fischer, B M Booth, B J Cuffel.   

Abstract

OBJECTIVE: The study examined the effect of medication noncompliance and substance abuse on symptoms of schizophrenia.
METHODS: Short-term inpatients with a diagnosis of schizophrenia were enrolled in a longitudinal outcomes study and continued to receive standard care after discharge. At baseline and six-month follow-up, Brief Psychiatric Rating Scale (BPRS) scores and data on subjects' reported medication compliance, drug and alcohol abuse, usual living arrangements, and observed side effects were obtained. The number of outpatient contacts during the follow-up period was obtained from medical records. Relationships between the dependent variables-medication noncompliance and follow-up BPRS scores-and the independent variables were analyzed using logistic and linear regression models.
RESULTS: Medication noncompliance was significantly associated with substance abuse. Subjects who abused substances, had no outpatient contact, and were noncompliant with medication had significantly greater symptom severity than other groups.
CONCLUSIONS: Substance abuse is strongly associated with medication noncompliance among patients with schizophrenia. The combination of substance abuse, medication noncompliance, and lack of outpatient contact appears to define a particularly high-risk group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837158     DOI: 10.1176/ps.47.8.853

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  51 in total

1.  Measuring readiness-to-change substance misuse among psychiatric outpatients: I. Reliability and validity of self-report measures.

Authors:  K B Carey; S A Maisto; M P Carey; D M Purnine
Journal:  J Stud Alcohol       Date:  2001-01

2.  Illicit drug use in heavy smokers with and without schizophrenia.

Authors:  Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

Review 3.  Enhancing validity in co-occurring disorders treatment research.

Authors:  Gregory J McHugo; Robert E Drake; Mary F Brunette; Haiyi Xie; Susan M Essock; Alan I Green
Journal:  Schizophr Bull       Date:  2006-07-18       Impact factor: 9.306

4.  Drug-related arrests in a cohort of public mental health service recipients.

Authors:  William H Fisher; Nancy Wolff; Albert J Grudzinskas; Kristen Roy-Bujnowski; Steven M Banks; Jonathan Clayfield
Journal:  Psychiatr Serv       Date:  2007-11       Impact factor: 3.084

Review 5.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 6.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 7.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

9.  Alcohol Use Disorder and the Persistence/Recurrence of Major Depression: Le trouble de l'usage de l'alcool et la persistance/récurrence de la dépression majeure.

Authors:  Vivian N Onaemo; Timothy O Fawehinmi; Carl D'Arcy
Journal:  Can J Psychiatry       Date:  2020-05-04       Impact factor: 4.356

10.  First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group.

Authors:  Kathleen Crebbin; Emma Mitford; Roger Paxton; Douglas Turkington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-01-27       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.